抗DNABII蛋白IHF抗体抑制鼻窦植入物生物膜
本研究探讨用抗DNABII蛋白整合宿主因子(IHF)抗体预处理鼻窦植入物材料,单独或联合阿莫西林-克拉维酸,能否预防不可分型流感嗜血杆菌(NTHI)生物膜形成。体外实验显示,抗IHF预处理显著降低三种材料上的细菌负荷(P ≤ 0.05),与阿莫西林-克拉维酸联用有协同作用并完全抑制生物膜形成。
要点
- 抗IHF抗体预处理可显著减少鼻窦植入物上的NTHI生物膜。
- 抗IHF联合阿莫西林-克拉维酸协同完全抑制生物膜形成。
- 单独阿莫西林-克拉维酸预处理无效。
核心结论
- 抗DNABII蛋白IHF抗体预处理鼻窦植入物材料可显著减少NTHI生物膜,与阿莫西林-克拉维酸联用协同完全抑制生物膜形成。
研究设计与样本
- 体外研究,将鼻窦植入物材料分别用抗IHF IgG富集抗血清、抗IHF联合阿莫西林-克拉维酸、生理盐水、IgG富集 naive 血清或单用阿莫西林-克拉维酸预处理后接种NTHI,16小时后定量细菌负荷。
主要发现
- NTHI在三种材料上均易形成生物膜,但抗IHF预处理使细菌负荷较对照显著下降(P ≤ 0.05)。
- 抗IHF联合阿莫西林-克拉维酸取得显著协同效果(P ≤ 0.05),完全抑制三种材料上的NTHI生物膜形成。
关键数值与推荐
- 抗IHF预处理较对照显著降低细菌负荷(P ≤ 0.05)。
- 抗IHF联合阿莫西林-克拉维酸协同完全抑制NTHI生物膜形成(P ≤ 0.05)。
临床怎么用
- 提示临床可用抗DNABII抗体预处理鼻窦植入物及其他手术材料以预防生物膜相关感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chronic rhinosinusitis is a common, costly condition often treated with endoscopic sinus surgery and intraoperative placement of intranasal sinus implant materials. Whereas these materials aid in postoperative healing, they also support bacterial biofilm formation and thus contribute to negative outcomes. This study examined pretreatment of sinus implant materials with antibody against an essential bacterial biofilm structural component, the DNABII family of DNA-binding proteins, as a strategy to prevent biofilm formation. METHODS: Sinus implant materials were equilibrated in immunoglobulin G (IgG)-enriched antiserum against the DNABII protein integration host factor (IHF), individually or in combination with amoxicillin-clavulanate prior to inoculation with nontypeable Haemophilus influenzae (NTHI), a predominant pathogen of chronic rhinosinusitis. After 16 hours, the bacterial burden was quantitated and compared to pretreatment with saline, IgG-enriched naive serum, or amoxicillin-clavulanate alone. RESULTS: NTHI readily formed biofilms on all three materials in vitro. However, pretreatment of each material with IgG-enriched anti-IHF resulted in a significant decrease in bacterial burden compared to controls (P ≤ 0.05). Moreover, a significant and synergistic outcome was achieved with a cocktail of anti-IHF plus amoxicillin-clavulanate (P ≤ 0.05) with complete inhibition of NTHI biofilm formation on all three materials. CONCLUSIONS: Biofilm formation was well supported in vitro on three sinus implant materials that vary in composition and resorption characteristics; however, pretreatment of each with DNABII protein targeted antibodies in combination with a previously ineffective antibiotic was highly effective to prevent the formation NTHI biofilms. These data demonstrate the potential for clinical utility of pretreatment of sinus implant and additional surgical materials with anti-DNABII antibodies. LEVEL OF EVIDENCE: NA Laryngoscope, 130:1364-1371, 2020.
引用
- Martyn L, Sethia R, Chon R, et al. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2019. PMID: 31314141. doi:10.1002/lary.28188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。